These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8448079)

  • 1. Escalating drug delivery in cancer chemotherapy: a review of concepts and practice--Part 2.
    Gurney H; Dodwell D; Thatcher N; Tattersall MH
    Ann Oncol; 1993 Feb; 4(2):103-15. PubMed ID: 8448079
    [No Abstract]   [Full Text] [Related]  

  • 2. Improved cancer chemotherapy. Benefits of delivery by infusion.
    Lokich JJ
    Postgrad Med; 1990 Feb; 87(2):239-41, 244-6. PubMed ID: 2300525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal delivery of dose in cancer chemotherapy with the support of haematopoietic growth factors.
    Trillet-Lenoir V; Arpin D; Brune J
    Eur J Cancer; 1993; 29A Suppl 5():S14-6. PubMed ID: 8260260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifractionated dosing for cancer chemotherapy: a novel schedule and a work in progress.
    Lokich J
    Cancer Invest; 1999; 17(7):551-4. PubMed ID: 10518201
    [No Abstract]   [Full Text] [Related]  

  • 5. Escalating drug delivery in cancer chemotherapy: a review of concepts and practice--Part 1.
    Gurney H; Dodwell D; Thatcher N; Tattersall MH
    Ann Oncol; 1993 Jan; 4(1):23-34. PubMed ID: 8435358
    [No Abstract]   [Full Text] [Related]  

  • 6. The calculation of received dose intensity.
    Hryniuk WM; Goodyear M
    J Clin Oncol; 1990 Dec; 8(12):1935-7. PubMed ID: 2230885
    [No Abstract]   [Full Text] [Related]  

  • 7. [Dose intensity in cancer chemotherapy (including high dose chemotherapy)].
    Ariyoshi Y; Ogawa M
    Gan To Kagaku Ryoho; 1994 Dec; 21(16):2699-707. PubMed ID: 7993104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The optimal scheduling of two drugs with simple resistance for a problem in cancer chemotherapy.
    Murray JM
    IMA J Math Appl Med Biol; 1997 Dec; 14(4):283-303. PubMed ID: 9415996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compliance and cancer chemotherapy.
    Green JA
    Br Med J (Clin Res Ed); 1983 Sep; 287(6395):778-9. PubMed ID: 6412825
    [No Abstract]   [Full Text] [Related]  

  • 10. On the MTD paradigm and optimal control for multi-drug cancer chemotherapy.
    Ledzewicz U; Schättler H; Gahrooi MR; Dehkordi SM
    Math Biosci Eng; 2013 Jun; 10(3):803-19. PubMed ID: 24063059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug dosage intensity--a panel discussion.
    McGuire WL; Goldie J; Hryniuk W; Tormey DC
    Breast Cancer Res Treat; 1987; 9(2):87-100. PubMed ID: 3620720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose combination chemotherapy: why, how, and when.
    Israël L
    Mt Sinai J Med; 1985 Jun; 52(6):447-51. PubMed ID: 3875024
    [No Abstract]   [Full Text] [Related]  

  • 13. Safer cancer chemotherapy using a kinetically-based experimental approach: higher dose intensity with reduced toxicity.
    Price LA
    Cancer Treat Rev; 1987 Dec; 14(3-4):215-23. PubMed ID: 3440249
    [No Abstract]   [Full Text] [Related]  

  • 14. A memetic algorithm for multiple-drug cancer chemotherapy schedule optimization.
    Tse SM; Liang Y; Leung KS; Lee KH; Mok TS
    IEEE Trans Syst Man Cybern B Cybern; 2007 Feb; 37(1):84-91. PubMed ID: 17278562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of tumours on normal cells and optimal chemotherapy regimens: the case of several drugs and toxicity constraints.
    Matveev AS; Savkin AV
    Math Med Biol; 2005 Jun; 22(2):143-62. PubMed ID: 15781427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining drugs and extending treatment - a PFS end point is not sufficient.
    Gyawali B; Prasad V
    Nat Rev Clin Oncol; 2017 Sep; 14(9):521-522. PubMed ID: 28534528
    [No Abstract]   [Full Text] [Related]  

  • 17. Dosing and sequencing for antineoplastic synergism in combination chemotherapy.
    Goldin A
    Cancer; 1984 Sep; 54(6 Suppl):1155-9. PubMed ID: 6467146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
    Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
    Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC/MEC/HEC).
    Schwartzberg L; Szabo S; Gilmore J; Haislip S; Jackson J; Jain G; Balu S; Buchner D
    Curr Med Res Opin; 2011 Apr; 27(4):837-45. PubMed ID: 21309647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.